CANCER FACTS AND ESTIMATES

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1515058
                    [Title] => Rx: Quality of life for lung cancer patients
                    [Summary] => 
Recently, we were invited to a symposium on the advances in the treatment and management of lung cancer.

                    [DatePublished] => 2015-10-26 10:00:00
                    [ColumnID] => 133914
                    [Focus] => 0
                    [AuthorID] => 1096607
                    [AuthorName] =>  Ching M. Alano
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 733958
                    [Title] => Roche lung cancer drug receives FDA approval
                    [Summary] => 
Pharmaceutical company Roche announced this week that the Philippine Food and Drug Administration (FDA) has approved its oral drug erlotinib as first-line therapy for people with advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.
                    [DatePublished] => 2011-10-06 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Rx: Quality of life for lung cancer patients

By Ching M. Alano | October 26, 2015 - 10:00am

Recently, we were invited to a symposium on the advances in the treatment and management of lung cancer.

Health And Family

Roche lung cancer drug receives FDA approval

October 6, 2011 - 12:00am

Pharmaceutical company Roche announced this week that the Philippine Food and Drug Administration (FDA) has approved its oral drug erlotinib as first-line therapy for people with advanced or metastatic non-small...

Science and Environment